Vaginal atrophy and genital pain in women on depot medroxyprogesterone acetate contraceptive injection.
atrophy
dyspareunia
medroxyprogesterone acetate
sexual dysfunction
vaginal diseases
Journal
The Australian & New Zealand journal of obstetrics & gynaecology
ISSN: 1479-828X
Titre abrégé: Aust N Z J Obstet Gynaecol
Pays: Australia
ID NLM: 0001027
Informations de publication
Date de publication:
10 Oct 2023
10 Oct 2023
Historique:
received:
20
06
2023
accepted:
25
09
2023
medline:
11
10
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
aheadofprint
Résumé
Depot medroxyprogesterone acetate causes a hypo-estrogenic state in over half of users although clinical vaginal atrophy causing superficial dyspareunia is thought rarely to occur. This is a case series of ten women using depot medroxyprogesterone acetate who presented with superficial dyspareunia and clinical vaginal atrophy. The women were treated with vaginal estriol cream and their contraception was discontinued or changed. All patients had either a complete resolution of symptoms or a substantial improvement at follow-up, and the clinical and laboratory findings of vaginal atrophy had resolved. This case series demonstrates that vaginal atrophy may occur more frequently than previously thought.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Références
Schivone G, Dorflinger L, Halpern V. Injectable contraception: Updates and innovation. Curr Opin Obstet Gynecol 2016; 28(6): 504-509.
Burke AE. The state of hormonal contraception today: Benefits and risks of hormonal contraceptives: Progestin-only contraceptives. Am J Obstet Gynecol 2011; 205(4 SUPPL): S17.
Black A, Guilbert E, Costescu D et al. Canadian contraception consensus (part 3 of 4): Chapter 8-progestin-only contraception. J Obstet Gynaecol Can 2016; 38(3): 279-300.
Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: A review. J Sex Med 2012; 9(9): 2213-2223.
Walker C, Badawy SZA. Vaginal atrophy following long-term depot medroxyprogesterone acetate use: A case report. Case Rep Obstet Gynecol 2013; 2013: 1-3.
Hodgins MB, Spike RC, Mackie RM, MacLean AB. An Immunohistochemical study of androgen, Oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol 1998; 105: 216-222.
Goldstein I, Dicks B, Kim NN, Hartzell R. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med 2013; 1(2): 44-53.
Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause 2021; 28(5): 579-588.
McEndree B. Clinical application of the vaginal maturation index. Nurse Pract 1999; 24(9): 48-56.
Haider S, Darney PD. Injectable contraception. Clin Obstet Gynecol 2007; 4: 898-906.
Miller L, Patton DL, Meier A et al. Depomedroxyprogesterone-induced Hypoestrogenism and changes in vaginal Flora and Epithelium. Obstet Gynecol 2000; 96: 431-439.
Ralph LJ, Gollub EL, Jones HE. Hormonal contraceptive use and women's risk of HIV acquisition: Priorities emerging from recent data. Curr Opin Obstet Gynecol 2015; 27(6): 487-495.